Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

HilleVax, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOSTON, AUG. 06, 2025 (GLOBE NEWSWIRE) -- HILLEVAX, INC. (NASDAQ: HLVX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL VACCINES, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE30, 2025. SECOND QUARTER FINANCIAL RESULTS AS OF JUNE30, 2025 AND DECEMBER31, 2024, THE COMPANY HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALING $159.5 MILLION AND $171.4 MILLION, RESPECTIVELY.

HILLEVAX REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (KSF) ARE INVESTIGATING THE PROPOSED SALE OF HILLEVAX, INC. (NASDAQGS: HLVX) TO XOMA ROYALTY CORPORATION (NASDAQGM: XOMA). UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF HILLEVAX WILL RECEIVE $1.95 IN CASH PER SHARE, PLUS ONE NON-TRANSFERABLE CONTINGENT VALUE RIGHT, REPRESENTING THE RIGHT TO RECEIVE ADDITIONAL PAYMENTS UNDER CERT.

HILLEVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF HILLEVAX, INC. - HLVX

BOSTON, MASS., AND EMERYVILLE, CALIF., AUG. 04, 2025 (GLOBE NEWSWIRE) -- HILLEVAX, INC. (HILLEVAX OR THE COMPANY) (NASDAQ: HLVX) AND XOMA ROYALTY CORPORATION (XOMA ROYALTY) (NASDAQ: XOMA) ANNOUNCED TODAY THEY HAVE ENTERED INTO A DEFINITIVE MERGER AGREEMENT (THE MERGER AGREEMENT), WHEREBY XOMA ROYALTY WILL ACQUIRE ALL OF THE ISSUED AND OUTSTANDING COMMON SHARES OF HILLEVAX.

HILLEVAX ENTERS INTO A DEFINITIVE AGREEMENT TO BE ACQUIRED BY XOMA ROYALTY FOR $1.95 IN CASH PER SHARE PLUS A CONTINGENT VALUE RIGHT

$159.5 MILLION OF CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH31, 2025 THE COMPANY IS EXPLORING THE POTENTIAL FOR CONTINUED DEVELOPMENT OF ITS NOROVIRUS VACCINE CANDIDATES INADULTS AS WELL AS BUSINESS DEVELOPMENT RELATED ACTIVITIES AND OTHER STRATEGIC ALTERNATIVES BOSTON, MAY 08, 2025 (GLOBE NEWSWIRE) -- HILLEVAX, INC. (NASDAQ: HLVX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL VACCINES, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH31, 2025. FIRST QUARTER FINANCIAL RESULTS AS OF MARCH31, 2025 AND DECEMBER31, 2024, THE COMPANY HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALING $159.5 MILLION AND $171.4 MILLION, RESPECTIVELY.

HILLEVAX REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS

PALO ALTO, CALIF.--(BUSINESS WIRE)--FRAZIER LIFE SCIENCES (FLS), A LONGSTANDING INVESTMENT FIRM FOCUSED ON INNOVATIVE THERAPEUTICS, TODAY ANNOUNCED THE APPOINTMENT OF ADITYA KOHLI, PH.D., TO PARTNER. SINCE JOINING FLS IN 2016, DR. KOHLI HAS PLAYED A FOUNDATIONAL ROLE IN COMPANY CREATION, CO-FOUNDING SIX LIFE SCIENCES COMPANIES, INCLUDING HILLEVAX (NASDAQ: HLVX, IPO IN 2022), PHATHOM PHARMACEUTICALS (NASDAQ: PHAT, IPO IN 2019), AND SCOUT BIO (ACQUIRED BY CEVA SANT ANIMALE). HE PREVIOUSLY ACTED.

FRAZIER LIFE SCIENCES APPOINTS ADITYA KOHLI TO PARTNER

$171.4 MILLION OF CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF DECEMBER31, 2024 THE COMPANY IS EXPLORING THE POTENTIAL FOR CONTINUED DEVELOPMENT OF ITS NOROVIRUS VACCINE CANDIDATES IN ADULTS AS WELL AS BUSINESS DEVELOPMENT RELATED ACTIVITIES AND OTHER STRATEGIC ALTERNATIVES BOSTON, MARCH 28, 2025 (GLOBE NEWSWIRE) -- HILLEVAX, INC. (NASDAQ: HLVX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL VACCINES, TODAY REPORTED FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER31, 2024. FULL YEAR 2024 FINANCIAL RESULTS AS OF DECEMBER31, 2024 AND DECEMBER31, 2023, THE COMPANY HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALING $171.4 MILLION AND $303.5 MILLION, RESPECTIVELY.

HILLEVAX REPORTS FULL YEAR 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS

NEW YORK, NY / ACCESSWIRE / AUGUST 28, 2024 / LEVI & KORSINSKY NOTIFIES INVESTORS THAT IT HAS COMMENCED AN INVESTIGATION OF HILLEVAX, INC. ("HILLEVAX") (NASDAQ:HLVX) CONCERNING POSSIBLE VIOLATIONS OF FEDERAL SECURITIES LAWS. ON JULY 8, 2024, HILLEVAX WAS THE SUBJECT OF A FIERCE BIOTECH ARTICLE.

LEVI & KORSINSKY INVESTIGATES POSSIBLE SECURITIES FRAUD VIOLATIONS BY HILLEVAX, INC. (HLVX)

$245.0 MILLION OF CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF JUNE 30, 2024 THE COMPANY IS EXPLORING THE POTENTIAL FOR CONTINUED DEVELOPMENT OF ITS HIL-214 AND HIL-216 NOROVIRUS VACCINE CANDIDATES IN ADULTS BOSTON, AUG. 08, 2024 (GLOBE NEWSWIRE) -- HILLEVAX, INC. (NASDAQ: HLVX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL VACCINES, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024 AND HIGHLIGHTED RECENT PROGRESS. RECENT BUSINESS HIGHLIGHTS IN Q3 2024, HILLEVAX ANNOUNCED THAT THE NEST-IN1 CLINICAL STUDY DID NOT MEET ITS PRIMARY OR SECONDARY EFFICACY ENDPOINTS AND THAT THE COMPANY WOULD DISCONTINUE FURTHER DEVELOPMENT OF HIL-214 IN INFANTS.

HILLEVAX REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS

NEW YORK, NY / ACCESSWIRE / JULY 19, 2024 / LEVI & KORSINSKY NOTIFIES INVESTORS THAT IT HAS COMMENCED AN INVESTIGATION OF HILLEVAX, INC. ("HILLEVAX") (NASDAQ:HLVX) CONCERNING POSSIBLE VIOLATIONS OF FEDERAL SECURITIES LAWS. ON JULY 8, 2024, HILLEVAX WAS THE SUBJECT OF A FIERCE BIOTECH ARTICLE.

HILLEVAX, INC. INVESTIGATED BY SHAREHOLDER RIGHTS ADVOCATES - INVESTORS SHOULD CONTACT LEVI & KORSINSKY REGARDING POTENTIAL SECURITIES LAW VIOLATIONS - HLVX

HilleVax, Inc.

HLVX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

HilleVax, Inc.

HLVX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

HLVX